Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

帕博西利布 来曲唑 医学 乳腺癌 肿瘤科 内科学 安慰剂 转移性乳腺癌 危险系数 雌激素受体 人口 癌症 妇科 三苯氧胺 置信区间 病理 替代医学 环境卫生
作者
Hope S. Rugo,Richard S. Finn,Veronique C Dieras,Johannes Ettl,Oleg Nikolaevich Lipatov,Anil Abraham Joy,Nadia Harbeck,Aurelio Bartolome Castrellon,Shrividya S. Iyer,Dongrui Ray Lu,Ave Mori,Eric Roland Gauthier,Cynthia Huang Bartlett,Karen A. Gelmon,Dennis J. Slamon
出处
期刊:Breast Cancer Research and Treatment [Springer Science+Business Media]
卷期号:174 (3): 719-729 被引量:443
标识
DOI:10.1007/s10549-018-05125-4
摘要

PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. METHODS: In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). RESULTS: After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. CONCLUSIONS: With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
DW的应助被捏鱼采纳,获得10
1秒前
搞怪的芾完成签到,获得积分10
1秒前
1秒前
Richardisme完成签到,获得积分10
1秒前
LIU发布了新的文献求助10
2秒前
荼蘼发布了新的文献求助10
2秒前
3秒前
3秒前
共享精神的应助被自觉的以寒采纳,获得10
4秒前
ppsy完成签到,获得积分10
4秒前
lll发布了新的文献求助10
4秒前
4秒前
tutu发布了新的文献求助10
4秒前
ket的应助被chen采纳,获得10
4秒前
甜甜的满天完成签到,获得积分10
5秒前
小二郎的应助被W1ndyKnight采纳,获得10
5秒前
5秒前
思源的应助被AA采纳,获得10
6秒前
XXX完成签到 ,获得积分10
7秒前
萍萍完成签到 ,获得积分10
7秒前
溺水小刀发布了新的文献求助10
8秒前
100发布了新的文献求助10
8秒前
nini发布了新的文献求助10
8秒前
syvshc的应助被小燕尾条采纳,获得10
8秒前
Yes完成签到,获得积分10
9秒前
李健的应助被浮晓采纳,获得10
9秒前
Eli发布了新的文献求助10
10秒前
风吹麦浪的应助被着急的焦采纳,获得10
10秒前
哭泣的凝芙完成签到,获得积分10
10秒前
汉堡包的应助被忐忑的远望采纳,获得10
11秒前
11秒前
红木完成签到 ,获得积分10
12秒前
炫迈口香糖完成签到,获得积分10
12秒前
zzzzzzzzz完成签到,获得积分10
12秒前
荼蘼发布了新的文献求助10
12秒前
啦啦啦发布了新的文献求助10
13秒前
bqys的应助被岳老师采纳,获得10
13秒前
平淡的觅波完成签到,获得积分10
13秒前
小手冰凉完成签到 ,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241